Although this axis is targeted by immune checkpoint inhibitors (ICIs), primary resistance occurs in approximately 70–80% of breast cancer patients and is caused by compensatory activation of alternative checkpoints (e.g., TIM-3 and LAG-3) [141]. Here, HAVCR2 is linked to breast cancer.